Hostname: page-component-89b8bd64d-mmrw7 Total loading time: 0 Render date: 2026-05-05T23:13:32.875Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of Baseline Anxiety on Well-being in People with Post-COVID-19 Condition: A Secondary Analysis

Published online by Cambridge University Press:  08 March 2024

Nicholas Kleine Open the ORCID record for Nicholas Kleine [Opens in a new window] ,
Angela T.H. Kwan Open the ORCID record for Angela T.H. Kwan [Opens in a new window] ,
Gia Han Le ,
Ziji Guo ,
Lee Phan ,
Mehala Subramaniapillai  and
Roger S. McIntyre Open the ORCID record for Roger S. McIntyre [Opens in a new window]
Nicholas Kleine
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Angela T.H. Kwan
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
Gia Han Le
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Institute of Medical Science, University of Toronto, Toronto, ON, Canada
Ziji Guo
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Lee Phan
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Mehala Subramaniapillai
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Roger S. McIntyre*
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada Department of Psychiatry, University of Toronto, Toronto, ON, Canada
*
Corresponding author: Roger S. McIntyre; Email: roger.mcintyre@bcdf.org
Rights & Permissions [Opens in a new window]

Abstract

Background

Post-COVID-19 condition (PCC) is associated with a host of psychopathological conditions including prominent anxiety symptoms. However, it is not known what effect anxious symptoms have on measures of well-being in individuals living with PCC. This study aims to evaluate anxiety’s association with measures of well-being in people with PCC.

Methods

This is a post hoc analysis utilizing data from a placebo-controlled, randomized, double-blind clinical trial assessing the effect of vortioxetine on cognitive impairment in individuals with PCC (NCT05047952). Baseline data with respect to anxiety and well-being were collected using the Generalized Anxiety Disorder Scale, 7-Item (GAD-7), and the World Health Organization (WHO) Well-Being Index, 5-Item (WHO-5), respectively. A generalized linear model (GLM) analysis on baseline GAD-7 and WHO-5 scores was conducted with age, sex, employment status, education level, previous major depressive disorder (MDD) diagnosis, and confirmed COVID-19 cases as covariates.

Results

Data was analyzed in a sample of 144 participants (N = 144). After controlling for the aforementioned covariates, the results found that GAD-7 and WHO-5 scores had a significant negative correlation (β = −0.053, p = <0.001), signifying that increased anxiety had adverse effects on the overall well-being of individuals with PCC.

Conclusion

Herein, we observed a clinically meaningful level of anxiety in individuals with PCC. We also identified a robust correlation between anxiety in PCC and measures of general well-being. Our results require replication, providing the impetus for recommending screening and targeting anxious symptoms as a tactic to improve general well-being and outcomes in individuals with PCC.

Keywords

Well-beingWHO-5anxietyGAD-7post-COVID-19 condition (PCC)long COVIDCOVID-19SARS-CoV-2post hoc analysis

Information

Type
Original Research
Information
CNS Spectrums , Volume 29 , Issue 2 , April 2024 , pp. 150 - 154
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Introduction

COVID-19 is an acute infectious disease that results in mild-to-moderate respiratory symptoms; however, more recently, researchers have shed light on the fact that COVID-19 extends beyond the initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, manifesting as long-term effects known as post-COVID-19 condition (PCC).Reference Wiersinga and Prescott1 The World Health Organization (WHO) defines PCC syndrome as a collection of debilitating symptoms in individuals who were formerly diagnosed with COVID-19, commencing within 3 months of infection and persisting for approximately 2 months.Reference Soriano, Murthy, Marshall, Relan and Diaz2 Global cumulative COVID-19 cases exceed 750 million with 10–20% of these individuals estimated to be “long haulers”.3, Reference Yan, Yang and Lai4 The debilitating effects of PCC are far-reaching, extending beyond respiratory disturbances to impact multiple organ systems, and are associated with a significant functional impairment.Reference Ceban, Ling and Lui5 The most notable burden is observed in the nervous, respiratory, musculoskeletal, and immune systems, with symptoms including cognitive impairment (i.e., “brain fog,” memory lapses, attention issues), fatigue, neuropsychiatric syndromes (i.e., depression, anxiety), dyspnea, and chronic pain.Reference Huang, Huang and Wang6

Comorbid neuropsychiatric syndromes are well documented in individuals with PCC, with a recent 6-month follow-up study revealing that approximately 23% of individuals with PCC reported increased symptoms of depression and anxiety.Reference Woo, Malsy and Pöttgen7 The aforementioned mental health-related difficulties, including anxiety and depression, are distinct from the cognitive impairments associated with PCC and uniquely impact an individual’s quality of life.Reference Premraj, Kannapadi and Briggs8 The prevalence and severity of these neuropsychiatric symptoms vary significantly, influenced by several risk factors. Keys among these are the severity of the initial SARS-CoV-2 infection and whether hospitalization or intensive care unit (ICU) intervention was necessary.Reference Al-Aly, Xie and Bowe9–Reference Wong, Shah, Johnston, Carlsten and Ryerson11 A recent meta-analysis highlighted that patient cohorts with >20% ICU admissions for acute SARS-CoV-2 infection showed markedly higher rates of anxiety and depression.Reference Al-Aly, Xie and Bowe9 Other contributing factors include gender, post-COVID-19 functional impairment, general fatigue, existing comorbidities, and a prior history of mental health issues.Reference Wong, Shah, Johnston, Carlsten and Ryerson11–Reference Ceban, Kulzhabayeva and Rodrigues13 Interestingly, reduced motivation has also been identified as an important correlate with neuropsychiatric symptom severity, suggesting a complex interplay between mental health and diminished well-being in PCC.Reference Wong, Shah, Johnston, Carlsten and Ryerson11, Reference Kwan, Al-Kassimi and Portnoff14, Reference McBride, Arden, Chater and Chilcot15

Well-being is a comprehensive domain that encompasses both the physical and neuropsychiatric outcomes associated with PCC. The aftermath of the COVID-19 pandemic has been correlated with a marked decrease in overall well-being, attributable to many factors that increase the risk of anxiety and depression including COVID-19 infection, financial stress, and social isolationReference Holmes, O’Connor and Perry16, Reference Diem, Schwarzwald and Friedli17 Furthermore, a recent survey conducted in Switzerland revealed that individuals suffering from PCC experience a significant decline in well-being, as measured by the WHO Well-Being Index, 5-Item (WHO-5).Reference Tleyjeh, Saddik and Ramakrishnan18 Analogous to neuropsychiatric disorders, the deterioration in well-being among individuals with PCC is linked to various risk factors, including age, physical comorbidities, and duration of COVID-19 symptoms.Reference Holm-Hadulla, Klimov, Juche, Möltner and Herpertz19

Although a direct correlation between anxiety and well-being in PCC remains to be established, anxiety disorders have well-characterized negative effects on well-being outside the context of PCC.Reference Lattie, Adkins, Winquist, Stiles-Shields, Wafford and Graham20, Reference McIntyre, Phan, Kwan, Mansur, Rosenblat, Guo, Le, Lui, Teopiz, Ceban, Lee, Bailey, Ramachandra, Di Vincenzo, Badulescu, Gill, Drzadzewski and Subramaniapillai21 The primary objective of this study is to evaluate the association between anxiety and measures of well-being in individuals with PCC. The findings of this research will ascertain whether anxiety serves as a predictor of diminished well-being in PCC and determine whether the WHO-5 can be a screening tool for anxiety in PCC.

Methods

Study design

This investigation is a post hoc analysis utilizing data from a recently published randomized, placebo-controlled, double-blind clinical trial (NCT05047952), which evaluated the efficacy of vortioxetine for treating cognitive deficits in individuals with PCC.Reference Orpana, Vachon, Pearson, Elliott, Smith and Branchard22 The study protocol was approved by Advarra, a local research ethics board that operates in compliance with Health Canada Regulations (IRB#00000971), and it was conducted in accordance with Good Clinical Practice principles and the Declaration of Helsinki. The manuscript reporting the primary outcomes of this trial is reported elsewhere.Reference McIntyre, Phan, Kwan, Mansur, Rosenblat, Guo, Le, Lui, Teopiz, Ceban, Lee, Bailey, Ramachandra, Di Vincenzo, Badulescu, Gill, Drzadzewski and Subramaniapillai21

Recruitment and study population

Participants were recruited in Canada between November 2021 and January 2023 through media promotions (i.e., Facebook, Instagram, Twitter, print ads) and by referral from an individual’s primary healthcare provider. All participants went through an initial virtual pre-screening where their eligibility to participate was assessed according to inclusion and exclusion criteria (Table S1 in the Supplementary Material). All eligible participants were required to be aged ≥18 years, be a current resident of Canada, meet the WHO definition of PCC, and have a documented history of SARS-CoV-2 infection. Acceptable proof of infection included a positive SARS-CoV-2 test (ie, polymerase chain reaction (PCR), antigen, or serology) or signed confirmation of clinical diagnosis by a healthcare provider. Eligible participants who provided written informed consent were enrolled in the study.

Randomization and masking

Eligible participants were randomly assigned in a 1:1 ratio to receive either vortioxetine (5–20 mg/day) or a placebo. The randomization process was carried out by staff members who were blinded to treatment assignments. All additional study personnel were blinded to treatment assignments, with an exception for two unblinded individuals who were responsible for dispensing the treatments. The two unblinded individuals did not interact with study participants. Further information on the clinical trial methodology is available in NCT05047952.

Outcome measures

Outcome measurements were collected at baseline (week 0) and at weeks 2, 4, and 8. The post hoc analysis herein analyzed baseline measures only. Baseline anxiety was measured by the Generalized Anxiety Disorder Scale, 7-Item (GAD-7). On the GAD-7, participants rank the degree to which generalized anxiety symptoms cause functional and/or social difficulties. A score of 0 on the GAD-7 suggests an individual has no anxiety, while the maximum score of 32 suggests an individual is suffering from severe anxiety. Baseline well-being was measured by the WHO-5. Higher scores on the WHO-5 denote higher well-being in the past 2 weeks, while any score < 13 denotes poor well-being.

Statistical analysis

All statistical analyses were conducted using Statistical Package for the Social Sciences (SPSS) version 28.0.1.1. A generalized linear model (GLM) analysis, with a Poisson probability distribution, was conducted to examine the relationship between baseline well-being (total WHO-5 scores) and anxiety (total GAD-7 scores). Participants’ age, sex, education level, and employment status, as well as the absence/presence of a previous major depressive disorder (MDD) diagnosis and confirmed COVID-19 case, were treated as covariates. Significance was determined at p < 0.001.

Results

Participant demographics

Baseline data was collected from a total of 147 individuals (N = 147), of whom 74 were randomized to the placebo group (n = 74) and 73 to the vortioxetine group (n = 73). Baseline demographics and clinical information, including age, sex, education level, employment status, previous MDD diagnosis, and confirmed COVID-19 diagnosis, were collected from all participants and incorporated into the GLM analysis as covariates. Notably, there was no significant difference in any of the baseline participant demographic and clinical characteristics between the vortioxetine and placebo groups (Table 1).

Table 1.

Baseline Characteristics of the Intent-to-Treat (ITT) Population (N = 147)

a T-test.

b Chi-square test.

* Two-sided p-values.

Impact of anxiety on general well-being

The GLM analysis examined the impact of GAD-7 scores on WHO-5 scores. Results from this analysis indicated that after controlling for the aforementioned covariates only baseline GAD-7 scores were significantly negatively correlated with baseline WHO-5 scores (β = −0.016, p < 0.001) (Table 2).

Table 2.

Generalized Linear Model of the Relationship Between GAD-7 and WHO-5 in People with Post-COVID-19 Condition

a T-test.

* p < 0.001.

Abbreviations: DV, dependent variable; GAD-7, Generalized Anxiety Disorder Scale, 7-Item; MDD, major depressive disorder; WHO-5, World Health Organization Well-Being Index, 5-Item.

Discussion

Key findings

In this post hoc analysis, we explored the effect of baseline anxiety on well-being in adults with PCC, as measured by GAD-7 and WHO-5 scores for anxiety and well-being, respectively. Herein, our GLM analysis identified a significant negative correlation between anxiety levels and well-being, suggesting that increased anxiety has detrimental effects on the general well-being in people with PCC. To our knowledge, this is the first study to report a correlation between anxiety symptoms and validated measures of well-being in individuals living with PCC. This finding is consistent with the broader understanding of anxiety’s negative impact on well-being. For instance, a recent Canadian study reported that individuals with mood or anxiety disorders had significantly lower levels of life satisfaction (LS) and self-rated mental health (SRMH).Reference Ghrouz, Noohu, Dilshad Manzar, Warren Spence, BaHammam and Pandi-Perumal23 Additionally, another study linked anxiety and depression with reduced sleep quality and physical activity, both key determinants of well-being.Reference Anderson and Shivakumar24

The findings from this analysis further emphasize the importance of mental health management in enhancing the overall well-being of patients with PCC. The positive effects of physical activity on mental health and well-being have been well established in the literature. Recent studies have evaluated these anxiolytic effects in PCC, demonstrating that physical rehabilitation can significantly improve anxiety symptoms and bolster improvements in quality of life in individuals with PCC.Reference McMahon, Corcoran and O’Regan25–Reference Kerksieck, Ballouz and Haile27 Additionally, the existing literature has also shown that psychological interventions can effectively improve anxiety related to PCC and address associated mental health concerns.Reference Priyamvada, Ranjan and Chaudhury28 The results of our study support these findings as we identified a strong correlation between anxiety and well-being in PCC. Enhancing well-being is not only vital for an individual’s health but may also help improve work productivity and reduce functional impairments, which are prevalent challenges faced by people with PCC.Reference Mazer and Ehrmann Feldman29

Strengths, limitations, and future directions

A strength of our analysis is the use of validated measures of anxiety and well-being. The WHO-5 has undergone rigorous evaluation as a screening instrument for mood disorders, particularly depression. In 2015, a comprehensive systematic review highlighted the WHO-5’s exceptional sensitivity in screening for depression in research participants.Reference Topp, Østergaard, Søndergaard and Bech30 Subsequent analyses have further corroborated this by identifying its validity in assessing depression in various disorders, including diabetes, human immunodeficiency virus (HIV), and acne vulgaris.Reference Rauwerda, Tovote and Peeters31–Reference Nolan, O’Donnell and Desderius33

There are methodological and conceptual aspects to consider that affect inferences and interpretations of our results. First, anxiety is one of many factors that can impact well-being. Notably, cognitive function has been recognized as a direct correlate of well-being.Reference Llewellyn, Lang, Langa and Huppert34 Cognitive impairment is recognized as the primary symptom of PCC, and therefore, it may also be involved in the lower well-being of people with PCC.Reference Woo, Malsy and Pöttgen7 This putative correlation warrants further exploration in future research endeavors. Also, it is important to highlight that this study is a post hoc analysis, and as such, the relationships between anxiety and well-being were not predefined as primary or secondary outcomes in the original study design.

Conclusion

In this study, we demonstrated that patients with PCC experience a significant increase in generalized anxiety symptoms. Furthermore, a robust negative correlation was identified between the levels of anxiety and overall well-being in individuals with PCC. These observations align with broader understandings of mental health and well-being but uniquely highlight this connection in the context of PCC for the first time. These results suggest that incorporating anxiety screening and anxiety-related therapeutic interventions could enhance the well-being of PCC patients. However, these conclusions are preliminary, as they are based on secondary analysis. Further research is needed to confirm these findings before they can be considered definitive.

Supplementary material

The supplementary material for this article can be found at http://doi.org/10.1017/S1092852924000099.

Author contribution

Conceptualization: R.S.M., A.T.H.K.; Data curation: R.S.M., A.T.H.K., L.P., Z.G.; Funding acquisition: R.S.M. Investigation: R.S.M., A.T.H.K., G.H.L., L.P., M.S., Z.G., N.K.; Methodology: R.S.M., A.T.H.K., G.H.L., L.P., M.S., Z.G., N.K.; Project administration: R.S.M., A.K., L.P., M.S.; Resources: R.S.M.; Software: R.S.M., A.T.H.K.; Supervision: R.S.M.; Validation: R.S.M., A.T.H.K.; Visualization: R.S.M., A.T.H.K.; Writing – review & editing: all authors; Formal analysis: A.T.H.K.; Writing – original draft: R.S.M., A.T.H.K., N.K.

References

Wiersinga, WJ, Prescott, HC. What is COVID-19? JAMA. 2020;324(8):816. doi:10.1001/jama.2020.12984.CrossRefGoogle ScholarPubMed
Soriano, JB, Murthy, S, Marshall, JC, Relan, P, Diaz, JV. WHO Clinical Case Definition Working Group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–e107. doi:10.1016/S1473-3099(21)00703-9.CrossRefGoogle Scholar
WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed October 26, 2023.Google Scholar
Yan, Z, Yang, M, Lai, CL. Long COVID-19 syndrome: a comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021;9(8):966. doi:10.3390/biomedicines9080966.CrossRefGoogle ScholarPubMed
Ceban, F, Ling, S, Lui, LMW, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93–135.CrossRefGoogle ScholarPubMed
Huang, C, Huang, L, Wang, Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232. doi:10.1016/S0140-6736(20)32656-8.CrossRefGoogle ScholarPubMed
Woo, MS, Malsy, J, Pöttgen, J, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020;2:fcaa205. doi:10.1093/braincomms/fcaa205.CrossRefGoogle ScholarPubMed
Premraj, L, Kannapadi, NV, Briggs, J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162. doi:10.1016/j.jns.2022.120162.CrossRefGoogle ScholarPubMed
Al-Aly, Z, Xie, Y, Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264. doi:10.1038/s41586-021-03553-9.CrossRefGoogle ScholarPubMed
Ceban, F, Ling, S, Lui, LMW, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93–135. doi:10.1016/j.bbi.2021.12.020.CrossRefGoogle ScholarPubMed
Wong, AW, Shah, AS, Johnston, JC, Carlsten, C, Ryerson, CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276. doi:10.1183/13993003.03276-2020.CrossRefGoogle ScholarPubMed
Mazza, MG, De Lorenzo, R, Conte, C, et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600. doi:10.1016/j.bbi.2020.07.037.CrossRefGoogle ScholarPubMed
Ceban, F, Kulzhabayeva, D, Rodrigues, NB, et al. COVID-19 vaccination for the prevention and treatment of long COVID: a systematic review and meta-analysis [published correction appears in Brain Behav Immun. 2023]. Brain Behav Immun. 2023;111:211–229. doi:10.1016/j.bbi.2023.03.022.CrossRefGoogle ScholarPubMed
Kwan, ATH, Al-Kassimi, K, Portnoff, JS, et al. Association of SARS-CoV-2 infection with neurological symptoms and neuroimaging manifestations in the pediatric population: a systematic review. Res Sq. 2023;170:90–110. rs.3.rs-2653722. doi:10.21203/rs.3.rs-2653722/v1.Google ScholarPubMed
McBride, E, Arden, MA, Chater, A, Chilcot, J. The impact of COVID-19 on health behavior, well-being, and long-term physical health. Br J Health Psychol. 2021;26(2):259–270. doi:10.1111/bjhp.12520.CrossRefGoogle ScholarPubMed
Holmes, EA, O’Connor, RC, Perry, VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020;7(6):547–560. doi:10.1016/S2215-0366(20)30168-1.CrossRefGoogle Scholar
Diem, L, Schwarzwald, A, Friedli, C, et al. Multidimensional phenotyping of the post-COVID-19 syndrome: a Swiss survey study. CNS Neurosci Ther. 2022;28(12):1953–1963. doi:10.1111/cns.13938.CrossRefGoogle ScholarPubMed
Tleyjeh, IM, Saddik, B, Ramakrishnan, RK, et al. Long term predictors of breathlessness, exercise intolerance, chronic fatigue and well-being in hospitalized patients with COVID-19: a cohort study with 4 months median follow-up. J Infect Public Health. 2022;15(1):21–28. doi:10.1016/j.jiph.2021.11.016.CrossRefGoogle ScholarPubMed
Holm-Hadulla, RM, Klimov, M, Juche, T, Möltner, A, Herpertz, SC. Well-being and mental health of students during the COVID-19 pandemic. Psychopathology. 2021;54(6):291–297. doi:10.1159/000519366.CrossRefGoogle ScholarPubMed
Lattie, EG, Adkins, EC, Winquist, N, Stiles-Shields, C, Wafford, QE, Graham, AK. Digital mental health interventions for depression, anxiety, and enhancement of psychological well-being among college students. Systematic review. J Med Internet Res. 2019;21(7):e12869. doi:10.2196/12869.CrossRefGoogle ScholarPubMed
McIntyre, RS, Phan, L, Kwan, ATH, Mansur, RB, Rosenblat, JD, Guo, Z, Le, GH, Lui, LMW, Teopiz, KM, Ceban, F, Lee, Y, Bailey, J, Ramachandra, R, Di Vincenzo, J, Badulescu, S, Gill, H, Drzadzewski, P, Subramaniapillai, M. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain. 2024;147:849–857. doi:10.1093/brain/awad377.CrossRefGoogle ScholarPubMed
Orpana, H, Vachon, J, Pearson, C, Elliott, K, Smith, M, Branchard, B. Correlates of well-being among Canadians with mood and/or anxiety disorders. Corrélats du bien-être chez les Canadiens présentant des troubles de l’humeur ou d’anxiété. Health Promot Chronic Dis Prev Can. 2016;36(12):302–313. doi:10.24095/hpcdp.36.12.04.CrossRefGoogle ScholarPubMed
Ghrouz, AK, Noohu, MM, Dilshad Manzar, M, Warren Spence, D, BaHammam, AS, Pandi-Perumal, SR. Physical activity and sleep quality in relation to mental health among college students. Sleep Breath. 2019;23(2):627–634. doi:10.1007/s11325-019-01780-z.CrossRefGoogle ScholarPubMed
Anderson, E, Shivakumar, G. Effects of exercise and physical activity on anxiety. Front Psychiatry. 2013;4:27. doi:10.3389/fpsyt.2013.00027.CrossRefGoogle ScholarPubMed
McMahon, EM, Corcoran, P, O’Regan, G, et al. Physical activity in European adolescents and associations with anxiety, depression and well-being. Eur Child Adolesc Psychiatry. 2017;26(1):111–122. doi:10.1007/s00787-016-0875-9.CrossRefGoogle ScholarPubMed
Fugazzaro, S, Contri, A, Esseroukh, O, et al. Rehabilitation interventions for post-acute COVID-19 syndrome: a systematic review. Int J Environ Res Public Health. 2022;19(9):5185. doi:10.3390/ijerph19095185.CrossRefGoogle ScholarPubMed
Kerksieck, P, Ballouz, T, Haile, SR, et al. Post COVID-19 condition, work ability and occupational changes in a population-based cohort. Lancet Reg Health Eur. 2023;31:100671. doi:10.1016/j.lanepe.2023.100671.CrossRefGoogle Scholar
Priyamvada, R, Ranjan, R, Chaudhury, S. Efficacy of psychological intervention in patients with post-COVID-19 anxiety. Ind Psychiatry J. 2021;30(Suppl 1):S41–S44. doi:10.4103/0972-6748.328787.CrossRefGoogle ScholarPubMed
Mazer, B, Ehrmann Feldman, D. Functional Limitations in Individuals With Long COVID. Arch Phys Med Rehabil. 2023;104(9):1378–1384. doi:10.1016/j.apmr.2023.03.004.CrossRefGoogle ScholarPubMed
Topp, CW, Østergaard, SD, Søndergaard, S, Bech, P. The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167–176. doi:10.1159/000376585.CrossRefGoogle ScholarPubMed
Rauwerda, NL, Tovote, KA, Peeters, ACTM, et al. WHO-5 and BDI-II are acceptable screening instruments for depression in people with diabetes. Diabet Med. 2018;35(12):1678–1685. doi:10.1111/dme.13779.CrossRefGoogle ScholarPubMed
Henkel, V, Moehrenschlager, M, Hegerl, U, Moeller, HJ, Ring, J, Worret, WI. Screening for depression in adult acne vulgaris patients: tools for the dermatologist. J Cosmet Dermatol. 2002;1(4):202–207. doi:10.1111/j.1473-2165.2002.00057.x.CrossRefGoogle ScholarPubMed
Nolan, CP, O’Donnell, PJM, Desderius, BM, et al. Depression screening in HIV-positive Tanzanian adults: comparing the PHQ-2, PHQ-9 and WHO-5 questionnaires. Glob Ment Health (Camb). 2018;5:e38. doi:10.1017/gmh.2018.31.CrossRefGoogle ScholarPubMed
Llewellyn, DJ, Lang, IA, Langa, KM, Huppert, FA. Cognitive function and psychological well-being: findings from a population-based cohort. Age Ageing. 2008;37(6):685–689. doi:10.1093/ageing/afn194.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Baseline Characteristics of the Intent-to-Treat (ITT) Population (N = 147)

Figure 1

Table 2. Generalized Linear Model of the Relationship Between GAD-7 and WHO-5 in People with Post-COVID-19 Condition

Supplementary material: File

Kleine et al. supplementary material

Kleine et al. supplementary material
Download Kleine et al. supplementary material(File)
File 16.2 KB